Literature DB >> 24826057

Aurora-A is a novel predictor of poor prognosis in patients with resected lung adenocarcinoma.

Bo Zeng1, Yiyan Lei1, Haoshuai Zhu1, Shenyuan Luo1, Mei Zhuang1, Chunhua Su1, Jianyong Zou1, Lei Yang1, Honghe Luo1.   

Abstract

BACKGROUND: The Aurora-A (Aur-A) gene, a key regulator of mitosis, has been proved as an oncogene in a variety of cancers. The Aur-A overexpression has been proved correlated with aggressiveness of cancer cells. However, the frequency of Aur-A protein overexpression, as well as its association with clinicopathologic parameters and prognosis remain unclear in lung adenocarcinoma (ADC). This study tried to clarify the clinical significance of Aur-A in patients with resected lung ADC. PATIENTS AND METHODS: A total of 142 informative patients with surgically resected lung ADC and 20 normal lung tissues were enrolled. Western blot and immunohistochemistry (IHC) were utilized to assess protein expression of Aur-A. RESULT: The expression of Aur-A was elevated in most of tumor tissues compared with the adjacent tissues by western blot. The IHC results showed that Aur-A protein was over-expressed in 98 of 142 (69.0%) tumor sections, while Aur-A was low-expressed in all normal lung sections. A positive correlation between Aur-A overexpression rate and ascending pathologic stages was observed (P<0.05). Kaplan-Meier analysis demonstrated that patients with Aur-A high expression had significantly inferior survival compared to those with Aur-A low expression. Both overall survival (OS) and disease-free survival (DFS) of positive overexpression patients were shorter than the negative group (P=0.036, P=0.041, respectively). Multivariate analysis confirmed that Aur-A expression, as an independent and significant factor for both DFS and OS, could predict a poor prognosis in patients with resected lung ADC (P=0.022, P=0.049, respectively).
CONCLUSIONS: Aur-A was overexpressed in lung ADC and overexpression of Aur-A might be a novel predictor for poor prognosis and potential therapeutic target in lung ADC.

Entities:  

Keywords:  Aurora-A (Aur-A); lung adenocarcinoma (ADC); prognosis

Year:  2014        PMID: 24826057      PMCID: PMC4000897          DOI: 10.3978/j.issn.1000-9604.2014.04.08

Source DB:  PubMed          Journal:  Chin J Cancer Res        ISSN: 1000-9604            Impact factor:   5.087


  29 in total

Review 1.  Roles of Aurora kinases in mitosis and tumorigenesis.

Authors:  Jingyan Fu; Minglei Bian; Qing Jiang; Chuanmao Zhang
Journal:  Mol Cancer Res       Date:  2007-01       Impact factor: 5.852

2.  Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer.

Authors:  Tatiana M Gritsko; Domenico Coppola; June E Paciga; Lin Yang; Mei Sun; Sue A Shelley; James V Fiorica; Santo V Nicosia; Jin Q Cheng
Journal:  Clin Cancer Res       Date:  2003-04       Impact factor: 12.531

3.  Identification of phosphorylated residues that affect the activity of the mitotic kinase Aurora-A.

Authors:  Laurie E Littlepage; Hua Wu; Thorkell Andresson; Julia K Deanehan; Laufey T Amundadottir; Joan V Ruderman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-06       Impact factor: 11.205

4.  Non-small cell lung cancer, version 2.2013.

Authors:  David S Ettinger; Wallace Akerley; Hossein Borghaei; Andrew C Chang; Richard T Cheney; Lucian R Chirieac; Thomas A D'Amico; Todd L Demmy; Ramaswamy Govindan; Frederic W Grannis; Stefan C Grant; Leora Horn; Thierry M Jahan; Ritsuko Komaki; Feng-Ming Spring Kong; Mark G Kris; Lee M Krug; Rudy P Lackner; Inga T Lennes; Billy W Loo; Renato Martins; Gregory A Otterson; Jyoti D Patel; Mary C Pinder-Schenck; Katherine M Pisters; Karen Reckamp; Gregory J Riely; Eric Rohren; Theresa A Shapiro; Scott J Swanson; Kurt Tauer; Douglas E Wood; Stephen C Yang; Kristina Gregory; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2013-06-01       Impact factor: 11.908

5.  The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma.

Authors:  Eiji Tanaka; Yosuke Hashimoto; Tetsuo Ito; Tomoyuki Okumura; Takatsugu Kan; Go Watanabe; Masayuki Imamura; Johji Inazawa; Yutaka Shimada
Journal:  Clin Cancer Res       Date:  2005-03-01       Impact factor: 12.531

6.  Amplification/overexpression of a mitotic kinase gene in human bladder cancer.

Authors:  Subrata Sen; Hongyi Zhou; Ruo-Dan Zhang; Dong S Yoon; Funda Vakar-Lopez; Shigemi Ito; Feng Jiang; Dennis Johnston; H Barton Grossman; Arnout C Ruifrok; Ruth L Katz; William Brinkley; Bogdan Czerniak
Journal:  J Natl Cancer Inst       Date:  2002-09-04       Impact factor: 13.506

7.  Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients.

Authors:  Charles N Landen; Yvonne G Lin; Anand Immaneni; Michael T Deavers; William M Merritt; Whitney A Spannuth; Diane C Bodurka; David M Gershenson; William R Brinkley; Anil K Sood
Journal:  Clin Cancer Res       Date:  2007-07-15       Impact factor: 12.531

8.  Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation.

Authors:  C Sakakura; A Hagiwara; R Yasuoka; Y Fujita; M Nakanishi; K Masuda; K Shimomura; Y Nakamura; J Inazawa; T Abe; H Yamagishi
Journal:  Br J Cancer       Date:  2001-03-23       Impact factor: 7.640

9.  Perimembrane Aurora-A expression is a significant prognostic factor in correlation with proliferative activity in non-small-cell lung cancer (NSCLC).

Authors:  Eiji Ogawa; Kazumasa Takenaka; Hiromichi Katakura; Masashi Adachi; Yosuke Otake; Yoshinobu Toda; Hirokazu Kotani; Toshiaki Manabe; Hiromi Wada; Fumihiro Tanaka
Journal:  Ann Surg Oncol       Date:  2007-11-28       Impact factor: 5.344

10.  Translational up-regulation of Aurora-A in EGFR-overexpressed cancer.

Authors:  Chien-Hsien Lai; Joseph T Tseng; Yi-Chao Lee; Ying-Ju Chen; Jeng-Chang Lee; Bo-Wen Lin; Tai-Chien Huang; Yao-Wen Liu; Tzeng-Horng Leu; Yi-Wen Liu; Ya-Ping Chen; Wen-Chang Chang; Liang-Yi Hung
Journal:  J Cell Mol Med       Date:  2009-10-03       Impact factor: 5.310

View more
  4 in total

1.  Suppression of Aurora-A-FLJ10540 signaling axis prohibits the malignant state of head and neck cancer.

Authors:  Chang-Han Chen; Alice Y W Chang; Shau-Hsuan Li; Hsin-Ting Tsai; Li-Yen Shiu; Li-Jen Su; Wen-Lung Wang; Tai-Jen Chiu; Sheng-Dean Luo; Tai-Lin Huang; Chih-Yen Chien
Journal:  Mol Cancer       Date:  2015-04-12       Impact factor: 27.401

2.  Aurora kinase A interacts with H-Ras and potentiates Ras-MAPK signaling.

Authors:  MaKendra Umstead; Jinglin Xiong; Qi Qi; Yuhong Du; Haian Fu
Journal:  Oncotarget       Date:  2017-04-25

3.  Aurora-A affects radiosenstivity in cervical squamous cell carcinoma and predicts poor prognosis.

Authors:  Yuhua Ma; Jie Yang; Ruozheng Wang; Zegao Zhang; Xiaoli Qi; Chunhua Liu; Miaomiao Ma
Journal:  Oncotarget       Date:  2017-05-09

4.  Aurora kinase A (AURKA) interaction with Wnt and Ras-MAPK signalling pathways in colorectal cancer.

Authors:  Annika Jacobsen; Linda J W Bosch; Sanne R Martens-de Kemp; Beatriz Carvalho; Anke H Sillars-Hardebol; Richard J Dobson; Emanuele de Rinaldis; Gerrit A Meijer; Sanne Abeln; Jaap Heringa; Remond J A Fijneman; K Anton Feenstra
Journal:  Sci Rep       Date:  2018-05-14       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.